On June 10, 2024 Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, reported the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled "Chimeric antigen receptor T cell therapy for autoimmune disease"1 (Press release, Kyverna Therapeutics, JUN 10, 2024, View Source [SID1234644232]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With more than 30 ongoing sponsored clinical trials and a growing number of published clinical evidence suggesting the potential of CAR T-cell therapy approaches for autoimmune diseases, the manuscript highlights key considerations on optimal target cell population, CAR construct design, acceptable toxicities, and potential for lasting immune reset.

"It is quite exciting to see how the learnings from the development of innovative CAR T-cell approaches for the treatment of cancer patients are now being applied to the treatment of patients with autoimmune diseases," said James Kochenderfer, M.D., senior investigator, clinician, and translational researcher in the Surgery Branch of the National Cancer Institute, National Health Institutes of Health in Bethesda, MD. "I look forward to seeing further progress in this emerging field ultimately leading towards a potential breakthrough in patient treatment."

"We are very proud of our scientific collaboration with widely recognized opinion leaders in CAR T-cell therapy," said Peter Maag, Ph.D., chief executive officer of Kyverna. "By rapidly advancing an evidence-based science we may bring potentially long-lasting, treatment-free therapeutic options to many patients in need."

About KYV-101
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine2.

KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 and Phase 2 trials of KYV-101 in the United States and Germany across two broad areas of autoimmune disease: rheumatology and neurology.

With 50 patients treated so far with the CAR in KYV-101 in both oncological and autoimmune conditions at more than 15 locations in Europe and the U.S., we believe that the differentiated properties of KYV-101 are critical for the potential success of CAR T cells as autoimmune disease therapies.

KYV-101 is also being evaluated in investigator-initiated trials for multiple indications in multiple geographies.

On June 10, 2024 Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF) a clinical stage pharmaceutical company that is dedicated to the research and development of light and/or radiation activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, reported that it’s lead compound, RuvidarTM, combined with transferrin to form the compound Rutherrin, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer ("NSCLC") (Press release, Theralase, JUN 10, 2024, View Source [SID1234644217]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Theralase recently completed experiments in NSCLC, using a Lewis Lung Cancer ("LLC1") orthotopic model. In this model, mouse lungs are subjected to lung cancer cells, which induces these mice to develop very aggressive, fast growing and metastatic lung tumours.

As shown in Figure 1, lung tumours retained Rutherrin longer than normal lung tissues (p> 0.01), leading to a substantially improved selectivity of Rutherrin to target lung cancer.

On June 10, 2024 Aktis Oncology, a clinical biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, reported that Matthew Roden, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024 at 9:20 a.m. ET (Press release, Aktis Oncology, JUN 10, 2024, View Source [SID1234644233]). The conference will be held virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 10, 2024 Green Data Center Real Estate has entered into a letter of intent to acquire Israeli biotech firm Vaxil Bio (Press release, Vaxil BioTherapeutics, JUN 10, 2024, View Source [SID1234648511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vaxil Bio is currently listed on the stock exchange and will divest all existing assets except cash to unrelated third parties.

The transaction is subject to regulatory approval and is due to close before the end of June. Other details related to the transaction have yet to be disclosed.

In connection with the acquisition, Green Data will also secure a loan, amounting to a minimum of C$2 million ($1.46m). The financing will be used for general corporate purposes and to fund the development of pipeline projects, said the company.

Green Data is a data center provider, that creates renewable generation and battery energy storage systems. The company was previously known as NuYen Enterprise Hosting and NuYen Blockchain before that, and currently has data centers in operation or under construction in Murphysboro, Illinois; New Mexico; and Canada.

Green Data is headed up by Jason Bak, the former CEO and chairman of Finavera Renewables and Solar Alliance.

Vaxil Bio is now headquartered in Toronto, Ontario, having been founded in Israel in 2007. The company almost closed on a similar merger with a copper mining company earlier this year. At the time Vaxil said: "The company will continue to actively explore other strategic options for maximizing shareholder value, including the continued development of Vaxil’s existing assets."

Prior to the letter of intent, Vaxil Bio specialized in immunotherapy of cancer and infectious diseases. The company’s lead product ImMucin was being developed to treat and prevent tuberculosis and Covid-19.

5X Capital Management is acting as the financial advisor to Green Data.

On June 10, 2024 Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, reported that it will be presenting a poster demonstrating the efficacy of its somatostatin receptor 2 (SST2) antagonist, SS0110 (satoreotide), relative to SST2-targeting agonists, at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held 8-11 June 2024 in Toronto, Canada (Press release, Ariceum Therapeutics, JUN 10, 2024, View Source [SID1234644218]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation entitled ‘[225Ac]Ac-SSO110 and [177Lu]Lu-SSO110 demonstrate significantly better efficacy than [225Ac]Ac-DOTA-TATE in the treatment of SST2-positive tumor xenografts’ compares satoreotide with the SST2 agonist, 225Ac-DOTATATE, and reveals that single doses of 20 MBq 177Lu-satoreotide or 30 kBq 225Ac-satoreotide induce significantly better efficacy than a single dose of 30 kBq 225Ac-DOTATATE. Most remarkably, 30 kBq 225Ac-satoreotide induced complete tumor regression in the NCI-H69 model, something not observed with the same or higher doses of 225Ac-DOTATATE.

These data highlight the significantly higher tumor uptake and longer tumor retention leading to a higher tumor to background and tumor to kidney ratios of satoreotide which translates into higher pre-clinical efficacy than SST2-targeting agonists when labelled with isotopes, 225Ac-satoreotide and 177Lu-satoreotide. This demonstrates the potential for satoreotide to clinically outperform SST2-targeting agonists and strongly supports its further clinical development for the treatment of SST2 positive tumors such as Small Cell Lung Cancer (SCLC) and Merkel Cell Carcinoma (MCC).

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "With this significant data we demonstrate that satoreotide has the potential to be a game changer for the treatment of SCLC and MCC. Satoreotide is multiple times more potent than DOTATATE, irrespective of the isotope, and this confirms the superiority of SST2 antagonist over agonist. We look forward to presenting our findings at this year’s SNMMI meeting."

Details of the poster presentation are as follow:

Title: [225Ac]Ac-SSO110 and [177Lu]Lu-SSO110 demonstrate significantly better efficacy than [225Ac]Ac-DOTA-TATE in the treatment of SST2-positive tumor xenografts

Authors: Anika Jaekel, Prachi Desai, Germo Gericke, Manuel Sturzbecher-Hoehne, Dennis Mewis & Manfred Rüdiger

Presenter: Anika Jaekel, Senior Director, Head of Translational Biology and Non-Clinical Pharmacology at Ariceum Therapeutics

Session: MTA07 POPs/Meet the Author: Oncology, Basic & Translational 2
Session Date and Time: Monday, June 10, 2024, 10:00 – 11:15 DST
Abstract ID: 242038